For example, a p110δ-selective inhibitor idelalisib was recently approved to treat several types of blood malignancies including chronic lymphocytic leukemia, relapsed follicular lymphoma, and relapsed small lymphocytic lymphoma44–46. The gene discussed is PIK3CD; the disease is follicular lymphoma.